Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CDNA 
CareDx Inc (CDNA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: CDNA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -44.12% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 995.45M USD | Price to earnings Ratio 19.09 | 1Y Target Price 32.5 |
Price to earnings Ratio 19.09 | 1Y Target Price 32.5 | ||
Volume (30-day avg) 768136 | Beta 1.95 | 52 Weeks Range 7.42 - 34.84 | Updated Date 04/1/2025 |
52 Weeks Range 7.42 - 34.84 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.93 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 15.74% | Operating Margin (TTM) -22.98% |
Management Effectiveness
Return on Assets (TTM) -7.01% | Return on Equity (TTM) 16.43% |
Valuation
Trailing PE 19.09 | Forward PE - | Enterprise Value 751522707 | Price to Sales(TTM) 2.98 |
Enterprise Value 751522707 | Price to Sales(TTM) 2.98 | ||
Enterprise Value to Revenue 2.25 | Enterprise Value to EBITDA -2.82 | Shares Outstanding 55425900 | Shares Floating 54089581 |
Shares Outstanding 55425900 | Shares Floating 54089581 | ||
Percent Insiders 3.58 | Percent Institutions 94.9 |
Analyst Ratings
Rating 3.88 | Target Price 34.67 | Buy 1 | Strong Buy 4 |
Buy 1 | Strong Buy 4 | ||
Hold 2 | Sell - | Strong Sell 1 | |
Strong Sell 1 |
Upturn AI SWOT
CareDx Inc
Company Overview
History and Background
CareDx, Inc. was founded in 1998 and is headquartered in South San Francisco, California. The company focuses on developing and marketing solutions for transplant patients, particularly in the area of transplant monitoring.
Core Business Areas
- Transplant Diagnostics: CareDx offers diagnostic tests that assess the health of transplanted organs, helping clinicians identify potential rejection early. These tests primarily use gene expression and donor-derived cell-free DNA (dd-cfDNA) to monitor transplant recipients.
- Transplant Solutions: CareDx provides digital solutions like AlloCare, a patient management platform, and iBox, an integrated suite of tools for transplant centers.
Leadership and Structure
The current CEO is Reg Seigler. CareDx operates with a functional organizational structure with key departments including R&D, Sales & Marketing, Operations, and Finance.
Top Products and Market Share
Key Offerings
- AlloSure: AlloSure is a donor-derived cell-free DNA (dd-cfDNA) test used to monitor the health of kidney, heart, and lung transplants. It detects early signs of organ rejection. CareDx estimated AlloSure revenue was approximately $265 million in 2023. Competitors include Natera (Prospera) and Eurofins Viracor (Tango).
- AlloMap: AlloMap is a gene expression test used to monitor heart transplant patients for rejection. AlloMap was the first commercially available gene expression test for heart transplant patients. CareDx estimated AlloMap revenue was approximately $70 million in 2023. Competitors include none, as this a very niche offering.
- AlloSeq: AlloSeq is a suite of HLA (human leukocyte antigen) typing solutions for donor-recipient matching in transplantation. No publicly available information on revenue. Competitors include Thermo Fisher Scientific and Qiagen.
Market Dynamics
Industry Overview
The transplant diagnostics market is growing due to increasing transplant volumes and the need for more precise and non-invasive monitoring solutions. It is driven by advancements in molecular diagnostics and genomics.
Positioning
CareDx is a leader in the transplant diagnostics market, particularly in non-invasive monitoring. Its key advantages are its established market presence, strong brand recognition, and comprehensive product portfolio.
Total Addressable Market (TAM)
The total addressable market for transplant diagnostics and monitoring is estimated to be several billion dollars globally. CareDx is positioned to capture a significant share of this market, leveraging its innovative technologies and strong relationships with transplant centers.
Upturn SWOT Analysis
Strengths
- Leading position in transplant diagnostics
- Established market presence and brand recognition
- Comprehensive product portfolio
- Strong relationships with transplant centers
- Innovative technology platform
Weaknesses
- Reliance on a few key products
- Regulatory and reimbursement risks
- Competition from larger diagnostic companies
- Lawsuit regarding business practices and data privacy
Opportunities
- Expanding into new transplant types
- Developing new diagnostic tests and solutions
- Geographic expansion into international markets
- Strategic partnerships and acquisitions
- Increasing adoption of non-invasive monitoring
Threats
- Increased competition from other diagnostic companies
- Changes in reimbursement policies
- Technological obsolescence
- Adverse regulatory actions
- Economic downturn
Competitors and Market Share
Key Competitors
- NTRA
- Euronfins Scientific (Not US traded)
Competitive Landscape
CareDx holds a significant position but faces increasing competition from larger diagnostic companies like Natera and other players. Competition occurs on price, convenience and data outcomes to help with transplant management.
Major Acquisitions
OTTR Chronicall
- Year: 2021
- Acquisition Price (USD millions): 16
- Strategic Rationale: Acquisition of patient management software company to help digitize workflow.
Growth Trajectory and Initiatives
Historical Growth: CareDx has experienced strong revenue growth driven by increased adoption of its diagnostic tests.
Future Projections: Analysts project continued revenue growth, driven by expansion into new markets and product lines. Profitability is a key focus for the company.
Recent Initiatives: CareDx has focused on expanding its product portfolio, including AlloSure and AlloMap, as well as strategic partnerships with transplant centers.
Summary
CareDx is a leading transplant diagnostics company with strong revenue growth and an established market presence. However, recent losses and the ongoing lawsuit are concerning. The company needs to focus on improving profitability and managing regulatory risks to maintain its competitive advantage. Continued innovation and strategic partnerships will be critical for future success.
Similar Companies
- NTRA
- TMO
- QGEN
Sources and Disclaimers
Data Sources:
- CareDx Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market conditions and company performance can change rapidly. Consult with a financial professional before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CareDx Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2014-07-17 | President, CEO & Director Mr. John Walter Hanna Jr. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 644 | Website https://caredx.com |
Full time employees 644 | Website https://caredx.com | ||
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI, a transplant quality tracking software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.